Payment overview · 2025
General Payments
$162.64
8 reported records · 6 companies
Healthcare provider profile · identity verified
Michael E. Obenshain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PEACHTREE CITY, GA · NPI 1528153723
Verified facts
What the public records show
CMS Open Payments records show Michael E. Obenshain, MD received $162.64 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.42 | 37.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.61 | 18.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.22 | 13.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.98 | 11.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.76 | 10.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $13.65 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $162.64 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.42 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.42 | 2 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 242 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
242 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
124 | 25 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1014 | 304 |
| Amlodipine Besylate | Amlodipine Besylate | 835 | 234 |
| Levothyroxine Sodium | Levothyroxine Sodium | 535 | 147 |
| Losartan Potassium | Losartan Potassium | 511 | 145 |
| Metformin Hcl | Metformin Hcl | 476 | 136 |
| Lisinopril | Lisinopril | 405 | 114 |
| Zolpidem Tartrate | Zolpidem Tartrate | 378 | 62 |
| Gabapentin | Gabapentin | 327 | 81 |
| Simvastatin | Simvastatin | 317 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 290 | 81 |
| Sertraline Hcl | Sertraline Hcl | 276 | 74 |
| Alprazolam | Alprazolam | 246 | 45 |
| Omeprazole | Omeprazole | 244 | 74 |
| Jardiance | Empagliflozin | 242 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 212 | 58 |
| Montelukast Sodium | Montelukast Sodium | 201 | 63 |
| Lorazepam | Lorazepam | 180 | 39 |
| Tramadol Hcl | Tramadol Hcl | 179 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 50 |
| Glimepiride | Glimepiride | 170 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 44 |
| Ozempic | Semaglutide | 152 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 38 |
| Trazodone Hcl | Trazodone Hcl | 132 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 34 |
| Rybelsus | Semaglutide | 124 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 34 |
| Potassium Chloride | Potassium Chloride | 111 | 24 |
| Glipizide Er | Glipizide | 110 | 23 |
| Atenolol | Atenolol | 109 | 30 |
| Clonazepam | Clonazepam | 109 | 15 |
| Meloxicam | Meloxicam | 104 | 36 |
| Allopurinol | Allopurinol | 99 | 27 |
| Bupropion Xl | Bupropion Hcl | 94 | 29 |
| Donepezil Hcl | Donepezil Hcl | 88 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 36 |
| Mounjaro | Tirzepatide | 86 | 11 |
| Farxiga | Dapagliflozin Propanediol | 84 | 14 |
| Finasteride | Finasteride | 83 | 22 |
| Buspirone Hcl | Buspirone Hcl | 77 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 19 |
| Trulicity | Dulaglutide | 66 | suppressed |
| Temazepam | Temazepam | 64 | suppressed |
| Synthroid | Levothyroxine Sodium | 63 | 17 |
| Metformin Hcl Er | Metformin Hcl | 61 | 20 |
| Ezetimibe | Ezetimibe | 58 | 21 |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Carvedilol | Carvedilol | 57 | 18 |
| Memantine Hcl | Memantine Hcl | 57 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 13 |
| Prednisone | Prednisone | 55 | 30 |
| Ondansetron Odt | Ondansetron | 53 | 18 |
| Valsartan | Valsartan | 51 | 15 |
| Famotidine | Famotidine | 49 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 15 |
| Spironolactone | Spironolactone | 47 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 46 | 12 |
| Furosemide | Furosemide | 46 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Fenofibrate | Fenofibrate | 41 | 12 |
| Lovastatin | Lovastatin | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 13 |
| Valacyclovir | Valacyclovir Hcl | 40 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Eliquis | Apixaban | 38 | suppressed |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Acyclovir | Acyclovir | 36 | suppressed |
| Prolia | Denosumab | 36 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 11 |
| Colchicine | Colchicine | 32 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Testosterone | Testosterone | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Ramipril | Ramipril | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 17 |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 11 |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Horizant | Gabapentin Enacarbil | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162.64 · 8 records | Novo Nordisk Inc | AREXVY, Fluad, Flucelvax, INTERSTIM, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, TZIELD, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error